Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $71.1 million.

  • Myriad Genetics' Net Cash Flow rose 129411.76% to $71.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 8442.62%. This contributed to the annual value of -$28.0 million for FY2024, which is 13788.9% down from last year.
  • As of Q3 2025, Myriad Genetics' Net Cash Flow stood at $71.1 million, which was up 129411.76% from -$17.9 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Net Cash Flow ranged from a high of $177.2 million in Q3 2021 and a low of -$92.6 million during Q1 2022
  • In the last 5 years, Myriad Genetics' Net Cash Flow had a median value of -$3.5 million in 2023 and averaged $2.0 million.
  • Data for Myriad Genetics' Net Cash Flow shows a peak YoY increase of 129411.76% (in 2025) and a maximum YoY decrease of 117857.14% (in 2025) over the last 5 years.
  • Myriad Genetics' Net Cash Flow (Quarter) stood at -$36.5 million in 2021, then fell by 23.29% to -$45.0 million in 2022, then skyrocketed by 222.67% to $55.2 million in 2023, then plummeted by 94.93% to $2.8 million in 2024, then skyrocketed by 2439.29% to $71.1 million in 2025.
  • Its Net Cash Flow was $71.1 million in Q3 2025, compared to -$17.9 million in Q2 2025 and -$11.0 million in Q1 2025.